Evidence map›Paper›PMID 42449979›Full record

ArticleInternational journal of molecular sciences2026

Nectin-4 Expression in Muscle-Invasive Bladder Cancer Is Associated with Growth-Related and Inflammatory Signaling Pathways.

Sebastian Jersinovic, Marko Vukovic, Jörg Hennenlotter, Thomas Lütfrenk, Tilman Todenhöfer, Arnulf Stenzl, Igor Tsaur, Steffen Rausch

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sebastian JersinovicDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.
Marko VukovicDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.ORCID 0000-0003-0265-4721
Jörg HennenlotterDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.ORCID 0000-0003-3827-6996
Thomas LütfrenkDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.
Tilman TodenhöferClinical Practice in Urology, 72622 Nuertingen, Germany.
Arnulf StenzlDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.ORCID 0000-0003-4207-9928
Igor TsaurDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.
Steffen RauschDepartment of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany.ORCID 0000-0002-6398-8701

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nectin-4 has emerged as a clinically relevant target in muscle-invasive bladder cancer (MIBC), primarily because of its role in antibody-drug conjugate-based therapies. However, the broader biological context of Nectin-4 expression and its association with tumor-promoting signaling pathways in MIBC remain insufficiently characterized. In this single-institution study, Nectin-4 expression (H-score 0-300) was assessed by immunohistochemistry in two independent MIBC cohorts. Associations between Nectin-4 expression and key markers related to growth signaling, metabolic regulation, and inflammation were analyzed alongside clinicopathological characteristics. Nectin-4 expression was significantly higher in malignant tissue than in non-malignant tissue (

Indexed as

Cell Adhesion MoleculesInflammationSignal TransductionUrinary Bladder NeoplasmsAgedAged, 80 and overBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNectinsNeoplasm InvasivenessPrognosisBiomarkers, TumorCell Adhesion MoleculesNECTIN4 protein, humanNectinsbiomarkerNectin-4prognosisurothelial cancer

Identifiers

PMID42449979
PMCPMC13361362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.